Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alliance Touts Imagent Synthetic Heart Imaging Agent As Easier To Store

This article was originally published in The Gray Sheet

Executive Summary

Alliance Pharmaceutical Corp. will launch its Imagent ultrasound heart imaging agent at the American Society of Echocardiography meeting in Orlando June 9-12

You may also be interested in...



Photogen Buys Alliance’s Imagent To Build Cardiovascular Imaging Franchise

Photogen Technologies' acquisition of Alliance Pharmaceutical's medical imaging assets provides a cardiovascular market entry at least three years ahead of the company's own internal R&D program

Photogen Buys Alliance’s Imagent To Build Cardiovascular Imaging Franchise

Photogen Technologies' acquisition of Alliance Pharmaceutical's medical imaging assets provides a cardiovascular market entry at least three years ahead of the company's own internal R&D program

Ultrasound contrast agents

Imavist contrast agent, developed jointly by Alliance Pharmaceutical and Schering AG, will enter a favorable reimbursement environment following FDA approval, the firms note. In July, CMS created new APCs defining ultrasound contrast agents as drugs and making them eligible for outpatient prospective "pass-through" payments covering 95% of their average wholesale cost, Alliance explains. The company has submitted the documentation requested by FDA in its August 2000 "approvable" letter and expects to launch the product by year-end

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel